

# Association between cardiovascular risk and moderate-severe obstructive sleep apnea in Chile

<b>Submission date</b> 12/07/2019	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 24/07/2019	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 04/09/2023	<b>Condition category</b> Nervous System Diseases	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Obstructive sleep apnea (OSA) is a breathing condition with an increased cardiovascular (heart disease) risk, especially those with moderate-severe OSA. Recent publications describe different subtypes of patients at the same OSA severity. In this setting, the presence of OSA and cardiovascular disease could define a potentially different phenotype with an increased risk of cardiovascular mortality. Other phenotypes are related to a different profile of patients according to a symptom-based approach, these patients report excessive sleepiness, snoring and high Epworth sleepiness scale. This subtype was independently associated with increased mortality risk. However, the prevalence of cardiovascular comorbidities and OSA subtypes in the Latino/Hispanic population is unclear. The aim of this study is to describe different subtypes of moderate-severe OSA in Chilean patients and to explore the association between these subtypes and cardiovascular comorbidities.

### Who can participate?

Patients over the age of 18 referred for the sleep study because of the clinical suspicion of OSA (snoring symptoms, apneas observed by bed partner or excessive daytime sleepiness or major cardiovascular comorbidities)

### What does the study involve?

The study includes participants with a recent diagnosis of moderate-severe OSA after a home sleep apnea test. Patients with mild and no OSA are defined as the control group. The aim is to define potential subtypes of patients using symptoms-based, oximetric-based and clinical-based approaches. The researchers also plan to describe different profiles of patients with moderate-severe OSA in Chile such as the elderly population, the female population, among others. Finally, the study explores the association between different oximeter measures reported in HSAT and cardiovascular outcomes, including mortality.

### What are the possible benefits and risks of participating?

There will be no immediate direct benefit to those taking part. Participants will receive the usual care.

Where is the study run from?  
Clínica Las Condes, Santiago (Chile)

When is the study starting and how long is it expected to run for?  
June 2009 to June 2025

Who is funding the study?  
Investigator initiated and funded

Who is the main contact?  
1. Jorge Jorquera, MD  
jjorquera@clinicalascondes.cl  
2. Gonzalo Labarca, MD FACP  
glabarc@gmail.com

## Contact information

**Type(s)**  
Public

**Contact name**  
Dr Jorge Jorquera

**ORCID ID**  
<https://orcid.org/0000-0003-4348-8678>

**Contact details**  
Estoril, 450. Las Condes. RM.  
Santiago  
Chile  
7591047  
+56 (0)992896812  
jjorquera@clinicalascondes.cl

**Type(s)**  
Scientific

**Contact name**  
Dr Gonzalo Labarca

**ORCID ID**  
<https://orcid.org/0000-0002-0069-3420>

**Contact details**  
Via del Rio, 3825. Chiguayante  
Concepcion  
Chile  
4100122  
+56 (0)978787484  
glabarc@gmail.com

# Additional identifiers

## Clinical Trials Information System (CTIS)

Nil known

## ClinicalTrials.gov (NCT)

Nil known

## Protocol serial number

E012018

# Study information

## Scientific Title

Prevalence of cardiovascular comorbidities and association with different subtypes of Chilean patients with moderate-severe Obstructive Sleep Apnea in Santiago (SantOSA)

## Acronym

SantOSA

## Study objectives

The researchers hypothesise that in Chilean patients with moderate-severe OSA, patients report different subtypes (phenotypes) according to clinical manifestations commonly found at sleep clinics and this association may be linked to an increased cardiovascular risk.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Approved January 2018, Ethics Committee of the Institution the Institution Review Board (Clinica Las Condes, Estoril 450, Las Condes, Santiago, Chile, ZIP: 7591047; Tel: +56 (0) 226103279; Email: cetica-secre@clinicalascondes.cl), IRB: 00008758

## Study design

Prospective cohort study

## Primary study design

Observational

## Study type(s)

Diagnostic

## Health condition(s) or problem(s) studied

Obstructive sleep apnea

## Interventions

The researchers developed a prospective cohort study of participants aged >18 years since 2009 who were prospectively included to date in a single tertiary center. They will include all participants who were referred for the sleep study who performed an ambulatory home sleep

apnea test (HSAT) because of the clinical suspicion of OSA (snoring symptoms, apneas observed by bed partner or excessive daytime sleepiness or major cardiovascular comorbidities).

Prior to the HSAT, a clinical examination and symptom standardized questionnaire was applied with the purpose of evaluating their sleep schedule, degree of daytime sleepiness, snoring, apnea observed by a bed partner, insomnia, episodes of nocturnal suffocation, and morning headache in addition to ESS. The study will include sociodemographic data, information about habits (tobacco and alcohol use), and anthropometric data (such as weight, height, body mass index (BMI) and neck circumference) were also recorded. The study also included the Flemons predictive model score (adjusted by neck circumference), nasal obstruction symptoms evaluation (NOSE), STOP-BANG and comorbidity characteristics at baseline (diagnosis of hypertension, T2DM, CHD, DLP, and stroke) and depression will be evaluated using the BECK questionnaire.

The researchers standardized the HSAT using an Embletta MPR equipment ([Embla Systems, USA) following the current recommendations and requirements of scientific societies for level III studies by American Society of Sleep Medicine (ASSM). OSA diagnosis requires an apnea-hypopnea index > 5 ev/hr, between 5-15 ev/hr is mild OSA and moderate-severe OSA requires an AHI > 15 ev/hr.

The plan is to categorize the data according to sleep apnea test results in two groups of analysis: the study group (moderate-severe OSA) and the control group (no OSA – mild OSA), for the control group, patients with other sleep apnea disorders after sleep study (including polysomnogram) study.

For a comprehensive analysis of different subtypes of patients, the researchers will explore different clinical subtypes through cluster analysis. For this purpose, they plan to develop a Latent class analysis, using a two-step auto-clustering process, and the number of clusters with the lowest Bayesian information will be selected as the number of clusters for further analysis. They plan to perform a sensitive analysis in order to define potentially subtype using: 1) a symptoms-based approach, 2) an oximetric-based approach and 3) a clinical-based approach.

The researchers also plan to perform a description of different profile of patients with moderate-severe OSA in Chile such as elderly population, female population, among others. Finally, they will explore the association between different oximeter measures reported in HSAT and cardiovascular outcomes, including mortality.

## **Intervention Type**

Other

## **Primary outcome(s)**

1. All-cause mortality measured through a review of the national register database (<https://www.registrocivil.cl>) at 3, 5 and 10 years
2. Cardiovascular mortality measured through a review of the national register database (<https://www.registrocivil.cl>) at 3, 5 and 10 years

## **Key secondary outcome(s)**

1. New onset of hypertension measured by either medical record or telephone consultation at 5 and 10 years
2. New onset of T2DM measured by either medical record or telephone consultation at 5 and 10 years

3. New onset of CHD measured by either medical record or telephone consultation at 5 and 10 years
4. New onset of atrial fibrillation measured by either medical record or telephone consultation at 5 and 10 years

**Completion date**

31/12/2035

## Eligibility

**Key inclusion criteria**

1. Participants aged >18 years
2. Referred for the sleep study because of the clinical suspicion of OSA (snoring symptoms, apneas observed by bed partner or excessive daytime sleepiness or major cardiovascular comorbidities)

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

**Key exclusion criteria**

1. Participants with other sleep disorders such as periodic limb movements of sleep (PLMS), NREM and arousal, REM and hypoxia, arousal and poor sleep
2. Participants who refuse to sign the consent form

**Date of first enrolment**

01/08/2009

**Date of final enrolment**

31/12/2025

## Locations

**Countries of recruitment**

Chile

**Study participating centre**

**Clinica Las Condes**  
Estoril 450, Las Condes, Región Metropolitana  
Santiago  
Chile  
7591047

## Sponsor information

**Organisation**  
Clinica Las Condes

**ROR**  
<https://ror.org/00j5bwe91>

## Funder(s)

**Funder type**  
Other

**Funder Name**  
Investigator initiated and funded

## Results and Publications

### Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication.

### IPD sharing plan summary

Other

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Interim results article</a>	oximetric parameter sub-analysis results	01/03/2021	03/04/2020	Yes	No
<a href="#">Interim results article</a>		28/07/2023	04/09/2023	Yes	No
<a href="#">Interim results article</a>		02/07/2021	04/09/2023	Yes	No
<a href="#">Interim results article</a>		04/01/2021	04/09/2023	Yes	No

<a href="#">Interim results article</a>		03/09/2020	04/09/2023	Yes	No
<a href="#">Interim results article</a>		10/04/2020	04/09/2023	Yes	No
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes